Guardant Health, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Brennan from TD Cowen reiterated a Buy rating on the stock and has a $72.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan has given his Buy rating due to a combination of factors that highlight Guardant Health’s strong position and future potential. The company showcased significant momentum across its business segments during its Investor Day, with an increase in 2028 sales and cash flow targets, which now exceed consensus expectations. Despite a slight decline in stock price due to market conditions, Guardant Health’s unique approach in the oncology diagnostics sector, particularly its focus on screening and epigenetics, sets it apart from competitors.
Furthermore, Brennan notes that Guardant Health’s strategic business review and recent momentum are expected to continue. The company has consistently delivered on its guidance updates and provided a comprehensive view of its technological advancements. Key factors supporting the Buy rating include Guardant’s ongoing improvements through epigenetics, a robust R&D cycle, and numerous upcoming catalysts in the MRD space. Additionally, updates on CGP FDA and ADLT, along with solid screening volume projections and new distribution deals, reinforce the company’s growth trajectory. As a result, Brennan has raised the price target from $63 to $72, reflecting higher forecasts and a strong valuation multiple.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $70.00 price target.
Based on the recent corporate insider activity of 166 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year.